Skip to main content
Premium Trial:

Request an Annual Quote

VWR to Distribute Kapa Biosystems' PCR Reagents in North America

Premium

Kapa Biosystems said this week that VWR International will distribute its PCR reagents in North America under a non-exclusive agreement.

The agreement gives VWR the rights to distribute Kapa's portfolio of products for applications such as high-fidelity PCR, fast PCR, long-range PCR, whole-blood PCR, crude-sample PCR, and single-protocol PCR.

Kapa said that its reagents are based on DNA polymerases that have been engineered to possess "unique amino acid modifications that confer dramatic improvements to the function of the enzymes."

The company's optimized polymerases include: KAPA2G FAST DNA Polymerase, which Kapa said is capable of synthesizing DNA in 50 percent less time than standard polymerase with high sensitivity; KAPA2G ROBUST DNA Polymerase, which is "more processive and tolerant of common PCR inhibitors carried over from DNA extraction;" KAPA HiFi DNA Polymerase, which exhibits "strong proofreading capability;" and KAPA Blood DNA Polymerase, which is able to amplify DNA direct from whole blood without the need for extraction.

VWR is a global laboratory supply and distribution company that recorded worldwide revenues of more than $3.7 billion in 2008.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.